RxDoctor Payments Data

Timothy Kennedy, MD

Surgical Oncology · New Brunswick, NJNPI 1235394255

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Intuitive Surgical at 42.5% of the total.

$4,151in general payments, 2019–2025

Across 38 payments — averaging $109.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Stryker$718
  • Dilon Technologies, Inc.$395
  • Johnson & Johnson$282
  • Medtronic$199
  • Applied Medical Resources Corporation$175
  • plus $618 from 5 others
$5,673,502in research payments, 2019–2025

Across 18 payments — averaging $315,195 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$5.7M

What the payments were for

  • Consulting fees$1754%
  • Travel & lodging$71817%
  • Food & beverage$2,15352%
  • Education$1,10627%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,151 in reported general payments places this provider in the 75th percentile of 59 surgical oncology providers in New Jersey.

See all surgical oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$88,019
Medicare patients
96
Services billed
261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →